🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. VGX-6150

    INOVIO PHARMACEUTICALS, INC.

    Hepatitis C, Chronic

    phase 1 mab completed

    1 trial

  2. VIR-1111

    Vir Biotechnology

    HIV I Infection

    phase 1 mab completed

    1 trial

  3. VIR-2218

    Vir Biotechnology

    Hepatic Impairment

    phase 1 small molecule active

    1 trial

  4. VIR-2218

    Vir Biotechnology

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  5. VK0214

    Viking Therapeutics

    Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)

    phase 1 small molecule completed

    1 trial

  6. VK4-116

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 1 small molecule active

    1 trial

  7. VSA001 injection

    Arrowhead Pharmaceuticals Ireland Limited

    Healthy Adult Volunteers

    phase 1 small molecule completed

    1 trial

  8. VTP-1000

    Barinthus Biotherapeutics plc.

    Celiac Disease

    phase 1 mab active

    1 trial

  9. VV261 5mg group

    Vigonvita Life Sciences

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  10. VX-118

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  11. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Focal Segmental Glomerulosclerosis (FSGS)

    phase 1 small molecule completed

    1 trial

  12. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  13. VX-433

    Vertex Pharmaceuticals (Australia) Pty.

    Narcolepsy Type 1 (NT1)

    phase 1 small molecule active

    1 trial

  14. VX-581

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    1 trial

  15. VX-634

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha 1-Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  16. VX-668

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha-1 Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  17. VX-840

    Vertex Pharmaceuticals (Australia) Pty.

    APOL1-mediated Kidney Disease

    phase 1 small molecule completed

    1 trial

  18. VX15/2503

    VACCINEX, INC.

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  19. VX15/2503

    VACCINEX, INC.

    Squamous Cell Carcinoma of the Head and Neck

    phase 1 mab active

    1 trial

  20. VX15/2503

    VACCINEX, INC.

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

  21. VY-AADC01

    NEUROCRINE BIOSCIENCES INC

    Idiopathic Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  22. VY-AADC01

    NEUROCRINE BIOSCIENCES INC

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  23. Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial

  24. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources